262 related articles for article (PubMed ID: 11501577)
1. Genes, chromatin, and breast cancer: an epigenetic tale.
Mielnicki LM; Asch HL; Asch BB
J Mammary Gland Biol Neoplasia; 2001 Apr; 6(2):169-82. PubMed ID: 11501577
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter.
Rice JC; Futscher BW
Nucleic Acids Res; 2000 Sep; 28(17):3233-9. PubMed ID: 10954590
[TBL] [Abstract][Full Text] [Related]
3. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer.
Yan L; Yang X; Davidson NE
J Mammary Gland Biol Neoplasia; 2001 Apr; 6(2):183-92. PubMed ID: 11501578
[TBL] [Abstract][Full Text] [Related]
4. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells.
Sirchia SM; Ferguson AT; Sironi E; Subramanyan S; Orlandi R; Sukumar S; Sacchi N
Oncogene; 2000 Mar; 19(12):1556-63. PubMed ID: 10734315
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modifications, chromatin distribution and TP53 transcription in a model of breast cancer progression.
Santos GC; da Silva AP; Feldman L; Ventura GM; Vassetzky Y; de Moura Gallo CV
J Cell Biochem; 2015 Apr; 116(4):533-41. PubMed ID: 25358520
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells.
Hitchler MJ; Oberley LW; Domann FE
Free Radic Biol Med; 2008 Dec; 45(11):1573-80. PubMed ID: 18845242
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic mechanisms of breast cancer: an update of the current knowledge.
Karsli-Ceppioglu S; Dagdemir A; Judes G; Ngollo M; Penault-Llorca F; Pajon A; Bignon YJ; Bernard-Gallon D
Epigenomics; 2014; 6(6):651-64. PubMed ID: 25531258
[TBL] [Abstract][Full Text] [Related]
8. Epigenomics and epigenetic therapy of cancer.
Brown R; Strathdee G
Trends Mol Med; 2002; 8(4 Suppl):S43-8. PubMed ID: 11927287
[TBL] [Abstract][Full Text] [Related]
9. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
[TBL] [Abstract][Full Text] [Related]
10. Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines.
Dagdemir A; Durif J; Ngollo M; Bignon YJ; Bernard-Gallon D
Epigenomics; 2013 Feb; 5(1):51-63. PubMed ID: 23414320
[TBL] [Abstract][Full Text] [Related]
11. Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells.
Mishra SK; Mandal M; Mazumdar A; Kumar R
FEBS Lett; 2001 Oct; 507(1):88-94. PubMed ID: 11682064
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of gelsolin expression in human breast cancer cells.
Mielnicki LM; Ying AM; Head KL; Asch HL; Asch BB
Exp Cell Res; 1999 May; 249(1):161-76. PubMed ID: 10328963
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
16. [Chromatin epigenetic modifications in cancer generation].
Arenas-Huertero F; Recillas-Targa F
Gac Med Mex; 2002; 138(6):547-55. PubMed ID: 12532619
[TBL] [Abstract][Full Text] [Related]
17. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer.
Baylin SB; Esteller M; Rountree MR; Bachman KE; Schuebel K; Herman JG
Hum Mol Genet; 2001 Apr; 10(7):687-92. PubMed ID: 11257100
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
Bhalla KN
J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
[TBL] [Abstract][Full Text] [Related]
19. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
[TBL] [Abstract][Full Text] [Related]
20. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
Aghdassi A; Sendler M; Guenther A; Mayerle J; Behn CO; Heidecke CD; Friess H; Büchler M; Evert M; Lerch MM; Weiss FU
Gut; 2012 Mar; 61(3):439-48. PubMed ID: 22147512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
